Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

6.700 +0.570 (+9.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,857,558
Open 6.180
Bid (Size) 6.600 (5)
Ask (Size) 6.700 (2)
Prev. Close 6.130
Today's Range 6.160 - 6.765
52wk Range 4.305 - 20.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Performance

YTD
-52.14%
-52.14%
1 Month
-0.45%
-0.45%
3 Month
+27.62%
+27.62%
6 Month
-57.70%
-57.70%
1 Year
-50.19%
-50.19%

More News

Read More
VERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV
From Rosen Law Firm
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
Via Benzinga
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
From Verve Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Invest Sells Coinbase Shares As Bitcoin Drops Below Key $62K Level
Via Benzinga
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
Via Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Via Benzinga
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
Via Benzinga
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Leadership Update
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
Via Benzinga
Topics ETFs
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
Via InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
Via InvestorPlace
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.